TIGIT and neoplasm: As such, immunotherapy directed towards damage- or pathogen-associated molecular patterns (DAMPs/PAMPs), toll-like receptors (TLRs), and other immunoregulatory domains such as Tcell immunoreceptors with Ig and ITIM domains (TIGIT) may further enhance anti-tumor immunity and could prove effective in patients whose disease is resistant to conventional immune checkpoint blockade [53].